Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
The treatment of carcinomatous meningitis in patients with non-small cell lung cancer is unsatisfactory with a median survival ranging from 4 to 6 weeks without treatment. This report presents a rare case of a long-term survivor with carcinomatous meningitis which was revealed during gefitinib therapy, and was treated with erlotinib. A 55-year-old female never-smoker was diagnosed with adenocarcinoma of the lung and underwent a right upper lobectomy. Four years had passed since surgery, she started gefitinib therapy for recurrent lung cancer. During gefitinib therapy, she presented with headache and was diagnosed with caricinomatous meningitis. After changing her treatment to erlotinib, her symptoms temporarily improved and she remained alive for 10 months. Erlotinib therapy may represent a candidate treatment option for carcinomatous meningitis after gefitinib therapy.
Thoracic Surgery Department, Kyushu Medical Center, Fukuoka, Japan. ttake@surg2.med.kyushu-u.ac.jp
Tomoyoshi
T
Takenaka
Motoyuki
M
Yamagata
Atsushi
A
Fukuda
Takashi
T
Sonoda
D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D055756:Meningeal Carcinomatosis / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D013129:Spinal Puncture
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib